医学
肝细胞癌
化疗
肿瘤科
内科学
自然杀伤细胞
肝细胞癌
免疫疗法
肝动脉灌注
淋巴因子激活杀伤细胞
临床试验
自然杀伤性T细胞
临床研究阶段
细胞疗法
胃肠病学
索拉非尼
癌
梅德林
癌症研究
抗体疗法
实体瘤疗效评价标准
细胞
免疫学
文本挖掘
病理
免疫系统
作者
Hyeon-Jong Kim,Yang Seok Koh,Byung Chan Lee,Yang-Hyun Baek,Jung Gil Park,Jeong Won Jang,Hyung-Seok Kim,Je-Jung Lee,Sung Bum Cho,Woo Kyun Bae
标识
DOI:10.4143/crt.2026.0477
摘要
Purpose: Hepatocellular carcinoma (HCC) refractory to locoregional therapies remains a major clinical challenge. This study evaluated the efficacy and safety of locoregional high-dose autologous natural killer (NK) cell therapy combined with hepatic arterial infusion chemotherapy (HAIC) in patients with locally advanced HCC. Materials and Methods: This open-label, multicenter, phase IIa study enrolled patients with locally advanced HCC refractory to standard care. Patients achieving stable disease (SD) or better after two HAIC cycles (5-fluorouracil and cisplatin) underwent two additional HAIC cycles followed by hepatic arterial NK cell infusion for up to two cycles. The primary endpoint was independent review committee (IRC)-assessed objective response rate (ORR). Secondary endpoints included investigator-assessed ORR, disease control rate (DCR), duration of response (DOR), time to progression (TTP), overall survival (OS), safety, and immunologic response. Tumor response was assessed per modified RECIST for HCC. Results: Of 17 enrolled patients, 16 were evaluable. IRC-assessed ORR was 68.75% (exact 95% confidence interval, 41.34-88.98) [complete response (CR): 18.75%; partial response (PR): 50.00%], and investigator-assessed ORR was 62.50%. Both assessments yielded a DCR of 100%. Median DOR was 12.65 and 10.48 months by IRC and investigator assessment, respectively. Median investigator-assessed TTP was 16.82 months; IRC-assessed TTP was not reached. Median OS was 24.05 months. No severe NK cell-related toxicities were observed. Conclusion: Locoregional high-dose autologous NK cell therapy following HAIC showed promising antitumor activity and an acceptable profile in selected patients with locally advanced HCC. These findings warrant validation in randomized trials designed to isolate the incremental contribution of NK cell therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI